p53 as a target for anti-cancer immunotherapy (Q41457944)

30 September 2017

1 reference

title

p53 as a target for anti-cancer immunotherapy (English)

1 reference

30 September 2017

1 reference

Chen HL

1

1 reference

30 September 2017

Carbone DP

series ordinal

2

1 reference

30 September 2017

publication date

1 April 1997

1 reference

Trends in Molecular Medicine

30 September 2017

published in

1 reference

30 September 2017

volume

3

1 reference

30 September 2017

issue

4

1 reference

30 September 2017

page(s)

160-167

1 reference

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Human tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

The p53 tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

The tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

The p53 proto-oncogene can act as a suppressor of transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Presence of a potent transcription activating sequence in the p53 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

WAF1, a potential mediator of p53 tumor suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

TP53 tumor suppressor gene: a model for investigating human mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Mutant Oncopeptide Immunization Induces CTL Specifically Lysing Tumor Cells Endogenously Expressing the Corresponding Intact Mutant p53

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

Genetic immunization is a simple method for eliciting an immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2897%2901003-4

7 January 2021

10.1016/S1357-4310(97)01003-4

Identifiers

DOI

1 reference

30 September 2017

1 reference